Tynski, the other encouraging sign is that these new directors are taking options deals exerciseable at $1 per share. So they obviously feel that if this is successful then it will go well north of $1.
As the Wise Owl report points out, the big outstanding issue is the success of this Phase 2 trial. Once they confirm they have a treatment that is at least as effective as its competitors, then they should grab market share due to the low side effects compared to existing treatments. So I expect the share to jump significantly on good news here.
But if the trial fails, better have a parachute handy.
The reason I'm encouraged though is that these guys have been at it for over 10 years now, and so far no bad results, just 'not there yet' results.
CBZ Price at posting:
48.6¢ Sentiment: Buy Disclosure: Held
